SUBSTITUTED PYRROLO[2,1,-ALPHA]PHTHALAZINES AND BENZO[g]PYRROL[2,1,-ALPHA]PHTHALAZINES AND THEIR USES IN THE TREATMENT OF CANCER

(19)

(11)

EP 3 710 005 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	14.06.2023 Bulletin 2023/24

(45)	Mention of the grant of the patent:
	24.08.2022 Bulletin 2022/34

(21)	Application number: 18879252.7

(22)	Date of filing: 16.11.2018

(51)

International Patent Classification (IPC):

C07D 487/04^(2006.01)
A61P 35/00^(2006.01)

A61K 31/5025^(2006.01)
A61P 35/02^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 31/5025; C07D 487/04; A61P 35/00; A61K 45/06; A61K 33/243; A61K 9/1271; A61P 35/02

	C-Sets:
	A61K 33/243, A61K 2300/00; A61K 31/5025, A61K 2300/00;

(86)	International application number:
	PCT/US2018/061400

(87)	International publication number:
	WO 2019/099755 (23.05.2019 Gazette 2019/21)

(54)

SUBSTITUTED PYRROLO[2,1,-ALPHA]PHTHALAZINES AND BENZO[g]PYRROL[2,1,-ALPHA]PHTHALAZINES AND THEIR USES IN THE TREATMENT OF CANCER

SUBSTITUIERTE PYRROLO[2,1,-ALPHA]PHTHALAZINE- UND BENZO[g]PYRROL[2,1,-ALPHA]PHTHALAZINEDERIVATE UND IHRE VERWENDUNG ZUR BEHANDLUNG VON KREBS

PYRROLO[2,1,-ALPHA]PHTHALAZINES ET BENZO[g]PYRROL[2,1,-ALPHA]PHTHALAZINES SUBSTITUÉS et LEURS UTILSATIONS DANS LE TRAITEMENT DU CANCEr

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

17.11.2017 US 201762587484 P

(43)	Date of publication of application:
	23.09.2020 Bulletin 2020/39

(73)	Proprietor: Academia Sinica
	Nankang, Taipei 115 (TW)

(72)	Inventors:
	SU, Tsann-long Amawalk NY 10501 (US) LEE, Te-chang Taipei 11521 (TW) CHEN, Tai-lin New Taipei City 220 (TW)

(74)	Representative: Lang, Christian
	LangPatent Anwaltskanzlei IP Law Firm Ingolstädter Straße 5 80807 München 80807 München (DE)

(56)

References cited: :

WO-A1-2016/144847
US-A- 4 960 775
US-A1- 2005 070 545
US-B2- 7 153 854

WO-A2-03/082208
US-A1- 2004 209 886
US-A1- 2010 184 771

LEE et al.: "Combination of Bifunctional Alkylating Agent and Arsenic Trioxide synergistically Suppresses the Growth of Drug-Resistant Tumor Cells", NEOPLASIA, vol. 12, no. 5, 2010, pages 376-387, XP055610931,

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).